Discover undervalued stocks with Eulerpool.

Subscribe for $2

Insulet Stock PODD

Price

0
Today +/-
-0
Today %
-0 %

Insulet stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Insulet stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Insulet stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Insulet stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Insulet's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Insulet Stock Price History

DateInsulet Price
10/6/20250 undefined
10/3/2025308.89 undefined
10/2/2025311.29 undefined
10/1/2025306.65 undefined
9/30/2025310.01 undefined
9/28/2025310.62 undefined
9/25/2025318.00 undefined
9/24/2025323.58 undefined
9/24/2025326.54 undefined
9/23/2025330.56 undefined
9/22/2025335.13 undefined
9/19/2025330.85 undefined
9/18/2025333.52 undefined
9/17/2025318.51 undefined
9/16/2025332.14 undefined
9/15/2025340.30 undefined
9/12/2025341.78 undefined
9/11/2025340.31 undefined
9/10/2025337.62 undefined
9/9/2025350.81 undefined
9/8/2025349.57 undefined

Insulet Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Insulet, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Insulet from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Insulet’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Insulet. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Insulet’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Insulet’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Insulet’s growth potential.

Insulet Revenue, EBIT and net profit per share

DateInsulet RevenueInsulet EBITInsulet Net Income
2030e5.16 B undefined0 undefined853.16 M undefined
2029e4.68 B undefined993.3 M undefined737.7 M undefined
2028e4.18 B undefined841.12 M undefined623.92 M undefined
2027e3.7 B undefined712.59 M undefined543.88 M undefined
2026e3.16 B undefined577.16 M undefined435.26 M undefined
2025e2.68 B undefined462.72 M undefined350.07 M undefined
20242.07 B undefined308.9 M undefined418.3 M undefined
20231.7 B undefined220 M undefined206.3 M undefined
20221.31 B undefined37.6 M undefined4.6 M undefined
20211.1 B undefined126 M undefined16.8 M undefined
2020904.4 M undefined51.5 M undefined6.8 M undefined
2019738.2 M undefined50 M undefined11.6 M undefined
2018563.8 M undefined40 M undefined3.3 M undefined
2017463.8 M undefined-7.4 M undefined-26.8 M undefined
2016367 M undefined-10.7 M undefined-28.9 M undefined
2015263.9 M undefined-48.7 M undefined-73.5 M undefined
2014231.3 M undefined-8.9 M undefined-51.5 M undefined
2013247.1 M undefined-29.2 M undefined-45 M undefined
2012211.4 M undefined-36 M undefined-51.9 M undefined
2011152.3 M undefined-40.8 M undefined-45.8 M undefined
201097 M undefined-34.2 M undefined-61.2 M undefined
200966 M undefined-59.4 M undefined-72.3 M undefined
200836.1 M undefined-81.1 M undefined-94.8 M undefined
200713.4 M undefined-52.8 M undefined-53.5 M undefined
20063.7 M undefined-34.6 M undefined-36.2 M undefined
2005100,000 undefined-21.5 M undefined-21.6 M undefined

Insulet Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
000000.010.040.070.10.150.210.250.230.260.370.460.560.740.91.11.311.72.072.683.163.74.184.685.16
-----333.33176.9283.3346.9756.7038.8217.06-6.4813.8539.5426.1621.6031.0822.4921.4618.8530.0422.0429.2118.1217.1812.8211.9910.15
-----400.00-92.31-11.1127.2744.3343.4243.6045.3454.9850.5757.4959.8365.7265.0464.3868.4961.6968.3069.7754.0045.7139.0134.5830.8828.03
000-0-0.01-0.01-00.020.040.070.090.110.130.130.210.280.370.480.580.750.811.161.45000000
-12-12-13-21-36-53-94-72-61-45-51-45-51-73-28-263116164206418350435543623737853
--8.3361.5471.4347.2277.36-23.40-15.28-26.2313.33-11.7613.3343.14-61.64-7.14-111.54266.67-45.45166.67-75.005,050.00102.91-16.2724.2924.8314.7318.3015.74
25.625.625.625.625.616.727.629.739.646.747.95455.656.857.3586162.365.968.669.973.6373.89000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Insulet Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Insulet is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (B)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
20052006200720082009201020112012201320142015201620172018201920202021202220232024
                                       
7.733.294.656.7128113.39457.3149.7151.2122.7298.6440.1288.9373.2944.8790623.4650.7953.4
0.11.44.8131516.823.233.333.139.942.528.853.476.782.883.8161205.6359.7365.5
00000000000000000000
0.93.4816.910.111.411.814.99.513.11235.533.871.4101154.3303.2346.8402.6430.4
1.11.81.421.30.93.74.55.9413.67.19.924.33465.875.6138.2169.9142
0.010.040.110.090.150.140.130.110.20.210.190.370.540.460.591.251.331.311.581.89
7.11721.317.615.512.519.425.432.437.141.846.3107.9258.4415.5493.6546.4625.9692.8759.8
000000000000125.5140.858.400000
00000000000000000000
00000029231814.10.90.54.410.413.228.736.675.598.798.5
00000037.537.537.537.539.639.739.839.639.839.839.851.751.751.5
0.10.30.72.23.11.32.72.21.80.320.2218.32562.196.2184162.1286.6
0.010.020.020.020.020.010.090.090.090.090.080.090.280.470.550.620.720.941.011.2
0.020.060.130.110.170.160.220.20.290.30.280.460.820.931.141.872.052.252.593.09
                                       
69.8119.50000000.10.10.10.10.10.10.10.10.10.10.10.1
000.250.280.380.450.510.530.650.660.690.740.870.90.751.261.211.041.11.18
-66.1-102-155.6-250.4-322.7-383.9-429.7-481.6-526.5-578-651.5-680.4-707.3-683.6-672-666.3-649.5-584.3-37840.3
0000000000-0.7-0.7-0.5-2.9-1.65.2-6.7-17-14.5-22.3
000000000000000.40.34.53722.59.1
00.020.090.030.060.070.080.040.120.080.030.060.160.210.080.60.560.480.731.21
1.63.54.57.35.94.911.49.419.414.715.213.224.425.554.554.137.730.819.219.8
1.34.24.57.3109.813.11919.524.736.74159.380.598.2133.1162.5249.1377.8412.6
0.12.21.42.444.23.55.50.91.67.71.32.49.6553.557.34.80
000000000000000000012.2
1.529.210.7000014.42.63.45.50.300015.625.127.549.483.8
4.539.121.11719.918.92848.342.444.465.155.886.1115.6157.7207.8228.8364.7451.2528.4
0.0100.020.060.090.070.110.10.120.170.170.330.570.590.891.041.251.371.371.3
00000000000000000000
0.30.31.4321.62.11.91.92.8456921.417.814.935.737.951.6
0.0100.020.060.090.070.110.110.120.170.180.340.570.60.911.061.261.411.41.35
0.010.040.040.080.110.090.140.150.160.210.240.390.660.721.071.271.491.771.861.88
0.020.060.130.110.170.160.220.20.290.30.280.460.820.931.141.872.052.252.593.09
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Insulet provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Insulet's financial health and stability.

Assets

Insulet's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Insulet must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Insulet after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Insulet's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
20042005200620072008200920102011201220132014201520162017201820192020202120222023
-13-21-36-53-94-72-61-45-51-45-51-73-28-263116164206
01246558111112151313152755576372
0000000-11000000000000
000-5-132-72-116-118-131-52-19-63-263-2-190
00242219322833428156688410710712115594105
001346-85-654432002213449
00000000000000023758
-13-20-31-50-82-49-35-25-2938-121541359884-68119145
-2-5-13-10-10-3-6-11-11-7-11-10-22-77-162-170-166-122-157-109
-2-6-12-10-10-3-6-49-11-7-11-15-178-210-184-7314-82-191-119
0000000-37000-4-155-133-229718040-33-10
00000000000000000000
01020-25329-33500-31-5174292-611612849-39-27
35050124194605410211741515-34509231626
35107012154123275539640176304-87360540-40-13
---------1.00-3.00-8.00-2.00-2.00-4.00-17.00-8.00-32.00-32.00-16.00-13.00
00000000000000000000
19-162561-3771-14-19-36921-2814135-15899708-115-11614
-15.8-25.8-44.9-60.5-92.6-52.4-42.1-36.6-40.1-4-2.6-23.2-6.2-36-126.5-72.5-82.5-190.8-38.336.5
00000000000000000000

Insulet stock margins

The Insulet margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Insulet. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Insulet.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Insulet's sales revenue. A higher gross margin percentage indicates that the Insulet retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Insulet's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Insulet's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Insulet's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Insulet. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Insulet's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Insulet Margin History

Insulet Gross marginInsulet Profit marginInsulet EBIT marginInsulet Profit margin
2030e69.79 %0 %16.55 %
2029e69.79 %21.22 %15.76 %
2028e69.79 %20.13 %14.93 %
2027e69.79 %19.24 %14.68 %
2026e69.79 %18.25 %13.77 %
2025e69.79 %17.29 %13.08 %
202469.79 %14.91 %20.19 %
202368.35 %12.96 %12.16 %
202261.72 %2.88 %0.35 %
202168.45 %11.47 %1.53 %
202064.39 %5.69 %0.75 %
201965.06 %6.77 %1.57 %
201865.66 %7.09 %0.59 %
201759.77 %-1.6 %-5.78 %
201657.52 %-2.92 %-7.87 %
201550.51 %-18.45 %-27.85 %
201454.95 %-3.85 %-22.27 %
201345.49 %-11.82 %-18.21 %
201243.66 %-17.03 %-24.55 %
201143.8 %-26.79 %-30.07 %
201045.05 %-35.26 %-63.09 %
200927.73 %-90 %-109.55 %
2008-12.74 %-224.65 %-262.6 %
2007-92.54 %-394.03 %-399.25 %
2006-324.32 %-935.14 %-978.38 %
2005-1,500 %-21,500 %-21,600 %

Insulet Stock Sales Revenue, EBIT, Earnings per Share

The Insulet earnings per share therefore indicates how much revenue Insulet has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Insulet earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Insulet's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Insulet’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Insulet's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Insulet Revenue, EBIT and net profit per share

DateInsulet Sales per ShareInsulet EBIT per shareInsulet Earnings per Share
2030e69.78 undefined0 undefined11.55 undefined
2029e63.34 undefined0 undefined9.98 undefined
2028e56.56 undefined0 undefined8.44 undefined
2027e50.13 undefined0 undefined7.36 undefined
2026e42.79 undefined0 undefined5.89 undefined
2025e36.22 undefined0 undefined4.74 undefined
202428.04 undefined4.18 undefined5.66 undefined
202323.05 undefined2.99 undefined2.8 undefined
202218.67 undefined0.54 undefined0.07 undefined
202116.02 undefined1.84 undefined0.24 undefined
202013.72 undefined0.78 undefined0.1 undefined
201911.85 undefined0.8 undefined0.19 undefined
20189.24 undefined0.66 undefined0.05 undefined
20178 undefined-0.13 undefined-0.46 undefined
20166.4 undefined-0.19 undefined-0.5 undefined
20154.65 undefined-0.86 undefined-1.29 undefined
20144.16 undefined-0.16 undefined-0.93 undefined
20134.58 undefined-0.54 undefined-0.83 undefined
20124.41 undefined-0.75 undefined-1.08 undefined
20113.26 undefined-0.87 undefined-0.98 undefined
20102.45 undefined-0.86 undefined-1.55 undefined
20092.22 undefined-2 undefined-2.43 undefined
20081.31 undefined-2.94 undefined-3.43 undefined
20070.8 undefined-3.16 undefined-3.2 undefined
20060.14 undefined-1.35 undefined-1.41 undefined
20050 undefined-0.84 undefined-0.84 undefined

Insulet business model

Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet is one of the most popular companies on Eulerpool.com.

Insulet SWOT Analysis

Strengths

Insulet Corp has developed a highly innovative technology in the form of its tubeless insulin delivery system known as the Omnipod. This technology provides significant benefits to diabetic patients, such as increased convenience, freedom, and improved glycemic control. The Omnipod's unique design has positioned the company as a market leader in the insulin pump industry.

Insulet Corp has established a strong market presence, with its products being widely recognized and accepted within the healthcare industry. This has enabled the company to secure partnerships with major insurers and healthcare providers, further enhancing its market position and ensuring steady revenue streams.

Weaknesses

Insulet Corp heavily relies on the success of its Omnipod system, as it is the company's primary source of revenue. While the technology has proven to be highly effective, any potential issues or competition in the market could significantly impact Insulet Corp's financial performance. Diversification of product offerings may be necessary to mitigate this weakness.

Despite its strong market presence in certain regions, Insulet Corp's global reach is relatively limited. The company primarily operates in North America, which exposes it to potential market saturation and barriers to international growth. Expanding into new markets and regions would help Insulet Corp diversify its customer base and decrease its dependence on a single market.

Opportunities

The global diabetic population is on the rise, creating a significant opportunity for Insulet Corp. As more individuals require insulin delivery systems, the demand for the company's innovative technology is expected to increase. Insulet Corp can capitalize on this growing market by expanding its product offerings and marketing efforts to reach a larger customer base.

The rapid advancements in connected devices and the Internet of Things (IoT) present an opportunity for Insulet Corp to enhance its insulin delivery system. By incorporating connectivity features and leveraging data analytics, the company can provide more personalized and effective solutions for diabetic patients. This would not only improve patient experience but also drive customer loyalty and market differentiation.

Threats

Insulet Revenue by Segment

  • 3 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Insulet Revenue by Segment

Segmente20232022202120202019201820172016
Total Omnipod-1.25 B USD1.01 B USD834.9 M USD----
U.S. Omnipod-884.8 M USD651.5 M USD526.9 M USD----
Total Omnipod Products1.66 B USD-------
U.S1.25 B USD-------
International Omnipod-363 M USD359.9 M USD308 M USD----
International410.1 M USD-------
Drug Delivery36 M USD57.5 M USD87.4 M USD69.5 M USD----

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Insulet Revenue by Segment

Segmente20232022202120202019201820172016
U.S. Omnipod-----323.47 M USD271.6 M USD229.79 M USD
Total Omnipod----673.5 M USD---
International Omnipod-----170.23 M USD119.95 M USD71.89 M USD
Drug Delivery----64.7 M USD60.02 M USD72.22 M USD65.32 M USD

Insulet Revenue by Region

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Insulet Revenue by Segment

DateAll otherInternationalU.SUnited States
2023-410.1 M USD1.29 B USD-
2022-363 M USD-942.3 M USD
2021-359.9 M USD-738.9 M USD
2020-308 M USD-596.4 M USD
2019253.1 M USD--485.1 M USD
2018172.02 M USD--391.8 M USD
2017119.95 M USD--343.82 M USD
201671.89 M USD--295.1 M USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Insulet Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Insulet historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Insulet shares outstanding

The number of shares was Insulet in 2024 — This indicates how many shares 73.89 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Insulet earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Insulet's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Insulet’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Insulet's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Insulet.

Insulet latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20250.95 1.17  (23.7 %)2025 Q2
3/31/20250.81 1.01  (24.51 %)2025 Q1
12/31/20241.05 1.15  (10.04 %)2024 Q4
9/30/20240.78 0.9  (15.86 %)2024 Q3
6/30/20240.57 0.55  (-4.03 %)2024 Q2
3/31/20240.4 0.73  (84.2 %)2024 Q1
12/31/20230.67 1.4  (108.8 %)2023 Q4
9/30/20230.41 0.71  (73.09 %)2023 Q3
6/30/20230.27 0.38  (41.69 %)2023 Q2
3/31/20230.11 0.23  (111.59 %)2023 Q1
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Insulet stock

Eulerpool World ESG Rating (EESG©)

74/ 100

🌱 Environment

64

👫 Social

94

🏛️ Governance

64

Environment

Scope 1 - Direct Emissions
1,383
Scope 2 - Indirect emissions from purchased energy
11,057
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
12,440
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees46
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Insulet shareholders

%
Name
Stocks
Change
Date
11.74333 % The Vanguard Group, Inc.8,677,15038,8906/30/2025
9.27896 % Fidelity Management & Research Company LLC6,856,220-271,1936/30/2025
6.40970 % Capital Research Global Investors4,736,127-1,340,4136/30/2025
5.88787 % BlackRock Institutional Trust Company, N.A.4,350,544-13,3996/30/2025
4.13621 % State Street Global Advisors (US)3,056,24632,7376/30/2025
2.88952 % Baillie Gifford & Co.2,135,068-115,6876/30/2025
2.60867 % Geode Capital Management, L.L.C.1,927,54358,3096/30/2025
2.07966 % ClearBridge Investments, LLC1,536,66456,6336/30/2025
1.77247 % American Century Investment Management, Inc.1,309,676157,0706/30/2025
1.52910 % Fidelity International1,129,851-155,3856/30/2025
1
2
3
4
5
...
10

Insulet Executives and Management Board

Dr. James Hollingshead

(61)
Insulet President, Chief Executive Officer, Director (since 2019)
Compensation 12.38 M

Mr. Eric Benjamin

(41)
Insulet Executive Vice President, Chief Product and Customer Experience Officer
Compensation 3.14 M

Mr. John Kapples

(64)
Insulet Senior Vice President, General Counsel
Compensation 2.47 M

Mr. Mark Field

(53)
Insulet Senior Vice President, Chief Technology Officer
Compensation 2.37 M

Mr. Dan Manea

(57)
Insulet Chief Human Resource Officer, Senior Vice President
Compensation 1.74 M
1
2
3
4

Insulet Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Amgen Stock
Amgen
SupplierCustomer0,84-0,650,13-0,18-0,49-0,44
Abbott Laboratories Stock
Abbott Laboratories
SupplierCustomer0,510,640,850,610,340,64
Olympic Circuit Tech Stock
Olympic Circuit Tech
SupplierCustomer-0,14-0,790,090,16-0,30-0,31
DexCom Stock
DexCom
SupplierCustomer-0,400,880,910,840,830,55
1

Most common questions regarding Insulet

What values and corporate philosophy does Insulet represent?

Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.

In which countries and regions is Insulet primarily present?

Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.

What significant milestones has the company Insulet achieved?

Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.

What is the history and background of the company Insulet?

Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.

Who are the main competitors of Insulet in the market?

The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.

In which industries is Insulet primarily active?

Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.

What is the business model of Insulet?

The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.

What is the P/E ratio of Insulet 2025?

The P/E ratio cannot be calculated for Insulet at the moment.

What is the P/S ratio of Insulet 2025?

The P/S cannot be calculated for Insulet currently.

What is the Quality Investing of Insulet?

The Quality Investing for Insulet is 6/10.

What is the revenue of Insulet 2025?

The expected Insulet revenue is 2.68 B USD.

How high is the profit of Insulet 2025?

The expected Insulet profit is 350.07 M USD.

What is the business model of Insulet

Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.

What is the Insulet dividend?

Insulet pays a dividend of 0 USD distributed over payouts per year.

How often does Insulet pay dividends?

The dividend cannot currently be calculated for Insulet or the company does not pay out a dividend.

What is the Insulet ISIN?

The ISIN of Insulet is US45784P1012.

What is the Insulet WKN?

The WKN of Insulet is A0MQX8.

What is the Insulet ticker?

The ticker of Insulet is PODD.

How much dividend does Insulet pay?

Over the past 12 months, Insulet paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Insulet is expected to pay a dividend of 0 USD.

What is the dividend yield of Insulet?

The current dividend yield of Insulet is .

When does Insulet pay dividends?

Insulet pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Insulet?

Insulet paid dividends every year for the past 0 years.

What is the dividend of Insulet?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Insulet located?

Insulet is assigned to the 'Health' sector.

Wann musste ich die Aktien von Insulet kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Insulet from 10/6/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2025.

When did Insulet pay the last dividend?

The last dividend was paid out on 10/6/2025.

What was the dividend of Insulet in the year 2024?

In the year 2024, Insulet distributed 0 USD as dividends.

In which currency does Insulet pay out the dividend?

The dividends of Insulet are distributed in USD.

All fundamentals about Insulet

Our stock analysis for Insulet Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Insulet Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.